HomeVarinel is a privately held, emerging pharmaceutical company developing novel drugs for treatment and/or prevention of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Friedreich's ataxia and amytrophic lateral sclerosis (ALS), known also as Lou Gehrig's disease. Varinel has built a strong technology base through close relationships and in-licensing programs with world-class academic investigators, commercial partners, and research foundations. In addition to private investment, the Company has funded its product development operations via competitive research grants obtained through private foundations focused on improving diagnosis and treatment outcomes for people with neurodegenerative disorders.Varinel has focused its product development efforts on multifunctional neuroprotective and neurorestorative drugs, which are characterized by unique combinations of activities, including: (1) selective iron chelation, reducing oxidative damage to brain cells caused by iron-catalyzed free radical reactions; (2) selective irreversible inhibition of the important mitochondrial brain enzymes, monoamine oxidases A and B (MAO-A and -B), providing for improved levels of neurotransmitters and other associated benefits; (3) heretofore unobserved neurorescue properties supporting growth of new neuronal tissue; and (4) anti-apoptotic properties that prevent the initiation of cell suicide programs in brain cells. |